Skip to main content

Table 1 Chromosomal regions described in the study of Van den Broek et al. [12] as associated with chemoradioresistance and chemoradiosensitivity and the specific alterations and putative candidate genes identified in the present study related to those already described

From: Genetic and epigenetic characterization of the tumors in a patient with a tongue primary tumor, a recurrence and a pharyngoesophageal second primary tumor

   

Present study

Chromosomal region

Type of alteration

Clinical association

Primary tumor

Recurrence

SPT

Possible candidate genes

3q21-q26.1

Gain

Chemoradioresistance

3q26.1

3q26.1

3q26.1

ZIC1, ZIC4

6p11-pter

 

6p25.3-p25.2

 

IRF4, HUS1B, FOXQ1, FOXC1, NQO2

 

6p21.33

 

CYP21A2, TNXB, STK19

 

6p12.1

 

GFRAL, HMGCLL1, BMP5

  

6p11.2

PRIM2

3q24

Amplification

3q24

3q24

3q24

-

7p11.2-12

 

7p12.1-p11.2

7p12.1-p11.2

EGFR

8p11.1

  

8p11.1

-

18p11.3

  

18p11.31-p11.23

LAMA1, PTPRM

3p11-pter

Loss

3p26.1

3p26.1

3p26.1

ARL8B

3p25.3

3p25.3

3p25.3

BRPF1, CIDEC, FANCD2, IRAK2, SEC13, TADA3, VHL

3p24.3

3p24.3

 

EFHB, RAB5A, C3orf48

3p22.3

3p22.3

 

TRIM71, CCR4

3p22.2

3p22.2

3p22.2

MLH1

3p21.31

3p21.31

3p21.31

DHX30, CDC25A, ATRIP, TREX1, SHISA5, PFKFB4, NCKIPSD, IP6K2, ARIH2, KLHDC8B, APEH, UBA7, RBM5

3p14.3

3p14.3

3p14.3

APPL1, ARF4, ARHGEF3, DNASE1L3, FLNB, HESX1, IL17RD, LRTM1, WNT5A

 

3p13

3p13

FOXP1, PPP4R2

4p11-pter

4p16.3

4p16.3

 

MXD4, TNIP2, NOP14

4p14

4p14

 

UGDH, UBE2K

11q distal

11q22.3

11q22.3

11q22.3

ATM

11q23.3

11q23.3

11q23.3

TAGLN, KMT2A, CBL, H2AFX

17p13.1 (TP53)

17p13.1

17p13.1

17p13.1

TP53

14q distal

Gain

Chemoradiosensitivity

14q32.33

14q32.33

14q32.33

-

17q

  

17q24.1-q24.2

PRKCA

  

17q25.1

TTYH2

22

22q11.23

22q11.23

22q11.23

GSTT1

2q31

Amplification

2q31.1

 

2q31.1

-

7q21

 

7q21.3

7q21.3

PEG10

14q13

 

14q13.3

14q13.3

PAX9

2q22-q25

Loss

2q24.2

2q24.2

 

MARCH7, CD302

7q11-q22

7q11.22 - q11.23

7q11.22 - q11.23

 

WBSCR22, CLDN3